<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/21CFR312.html">Part 312
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 312.31  Information amendments.
                            </h3>
                            <p class="depth1"><em>(a)</em> Requirement for information amendment. A sponsor shall report in an information amendment essential information on the IND that is not within the scope of a protocol amendment, IND safety reports, or annual report. Examples of information requiring an information amendment include:</p><p class="depth2"><em>(1)</em> New toxicology, chemistry, or other technical information; or</p><p class="depth2"><em>(2)</em> A report regarding the discontinuance of a clinical investigation.</p><p class="depth1"><em>(b)</em> Content and format of an information amendment. An information amendment is required to bear prominent identification of its contents (e.g., ``Information Amendment: Chemistry, Manufacturing, and Control'', ``Information Amendment: Pharmacology-Toxicology'', ``Information Amendment: Clinical''), and to contain the following:</p><p class="depth2"><em>(1)</em> A statement of the nature and purpose of the amendment.</p><p class="depth2"><em>(2)</em> An organized submission of the data in a format appropriate for scientific review.</p><p class="depth2"><em>(3)</em> If the sponsor desires FDA to comment on an information amendment, a request for such comment.</p><p class="depth1"><em>(c)</em> When submitted. Information amendments to the IND should be submitted as necessary but, to the extent feasible, not more than every 30 days.
[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 53 FR 1918, Jan. 25, 1988; 67 FR 9585, Mar. 4, 2002]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
